Kelun-Biotech Entered into a Research Collaboration and Exclusive License Agreement with MSD to Develop ADC for Solid Tumors
Shots:
- Kelun-Biotech to receive $35M up front & is eligible to receive $901M in development, approval & commercial milestones along with royalties. Both companies will collaborate on early clinical development plans for SKB-264 as a monothx. & in combination with Keytruda in advanced solid tumors
- MSD gets an exclusive right to develop, manufacture & commercialize ADC. The collaboration will strengthen & diversifies MSD’s oncology pipeline for ADCs to treat cancer
- The collaboration also combines MSD’s expertise with Kelun-Biotech’s innovation power to generate development synergy & advance the development & commercialization of the collaboration programs. MSD will exercise an option for global rights to SKB-264 (Ex- Greater China)
Ref: GlobalNewswire | Image: Kelun-Biotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
